← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $168B	3,195	-68	-2%	$197B
2	2 Eli Lilly LLY $1.12T	2,343	+39	+2%	$226B
3	3 Amgen AMGN $234B	2,336	+43	+2%	$102B
4	4 Becton Dickinson BDX $51.9B	1,577	+9	+0.6%	$63.2B
5	5 McKesson MCK $117B	1,138	+41	+4%	$39.5B
6	6 Regeneron Pharmaceuticals REGN $81.2B	1,095	+17	+2%	$64.5B
7	7 AstraZeneca AZN $255B	983	+33	+3%	$34.3B
8	8 Novo Nordisk NVO $171B	901	+16	+2%	$15.2B
9	9 Conagra Brands CAG $6.83B	751	-23	-3%	$13.7B
10	10 West Pharmaceutical WST $26.8B	716	-13	-2%	$28.2B
11	11 ResMed RMD $33.5B	682	-42	-6%	$23.6B
12	12 DELISTED CATALENT, INC. CTLT	536	-26	-5%	$19.9B
13	13 Lamb Weston LW $7.35B	527	-21	-4%	$7.48B
14	14 DaVita DVA $12B	510	+18	+4%	$9.27B
15	15 Teva Pharmaceutical Industries Limited TEVA $47.9B	438	-12	-3%	$4.83B
16	16 Inspire Medical Systems INSP $2B	299	+10	+3%	$6.92B
17	17 Medifast MED $134M	288	-9	-3%	$1.7B
18	18 Accendra Health ACH $17.7M	265	-6	-2%	$3.39B
19	19 BellRing Brands BRBR $1.06B	253	+100	+65%	$2.48B
20	TWNK 20 DELISTED Hostess Brands, Inc. Class A Common Stock TWNK	250	+51	+26%	$3.15B
21	21 Herbalife HLF $1.53B	229	-16	-7%	$3.1B
22	22 Opko Health OPK $1.17B	229	-6	-3%	$671M
23	23 DELISTED WW International WW	213	+13	+7%	$691M
24	24 Amphastar Pharmaceuticals AMPH $1.09B	203	+35	+21%	$1.07B
25	25 MannKind Corp MNKD $974M	185	-6	-3%	$418M